TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03604445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion
Study: NCT03654846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmergencyEye
Description: EmergencyEye Smartphone App
Study: NCT02050269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Iohexol, 300 mg/mL
Study: NCT00440505

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (5 mg)
Description: Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (10 mg)
Description: Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
Study: NCT04617158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjustable strabismus surgery
Description: Adjustable surgery will be done using sliding nose technique using fornix approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjustable strabismus surgery
Description: Adjustable surgery will be done using sliding nose technique using fornix approach
Study: NCT00262054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Un-fractionated heparin
Description: UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
Study: NCT00300742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate up to 300 mg per day.
Study: NCT03558880

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block was performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Anesthesia
Description: Tumescent Anesthesia was applied
Study: NCT02468245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weekly telephone follow up
Description: For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
Study: NCT00294762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV
Study: NCT00846950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexchlorpheniramine, lorazepam
Study: NCT04022395

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: stress cardiac MRI
Description: pharmacological stress testing has evolved as an alternative to physical exercise for the detection of inducible myocardial ischemia
Study: NCT05056584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon infusion
Description: One hour glucagon-clamp followed by one hour of blood sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon infusion
Description: One hour glucagon-clamp followed by one hour of blood sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon infusion
Description: One hour glucagon-clamp followed by one hour of blood sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primed tracer infusion
Description: Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primed tracer infusion
Description: Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primed tracer infusion
Description: Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
Study: NCT01753908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout Extract
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Urinary ITCs and metabolites measured

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Urinary ITCs and metabolites measured

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT03391947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: semilunar coronally positioned flap
Description: The description of this intervention has been already given before

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: The description of this intervention has been already given before
Study: NCT00215605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
Study: NCT02849639

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive educational materials, but will not receive MTM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Therapy Management (MTM)
Description: Participants will receive MTM in addition to the educational materials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine patch
Description: At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine patch
Description: At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
Study: NCT01006070

Intervention type: PROCEDURE
Intervention: kyphoplasty
Description: surgical kyphoplasty

Intervention type: PROCEDURE
Intervention: kyphoplasty
Description: surgical kyphoplasty
Study: NCT04855994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: The investigators performed Paravertebral block to that patient group for postoperative analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectoral block
Description: The investigators performed pectoral block to that patient group for postoperative analgesia
Study: NCT04213859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRET - Virtual Reality Exposure Therapy
Description: VRET will include 4 weekly 1-hour sessions over the course of 4 weeks. The treatment protocol is based on the Virtual Reality (VR) treatment manual guidelines (Rothbaum \& Hodges, 1997,1999) and includes psychoeducation, anxiety management training, cognitive restructuring and exposure. The first therapy session focuses on creating an individually-tailored conceptualization and treatment plan. Following this process, participant and therapist conduct a short introductory VR flight exposure simulation to familiarize the participant with the VRET apparatus. The VRET apparatus is an advanced, large-scale VR system that allows maximal immersion within the virtual environment. The second, third and fourth sessions include psychoeducation, relaxation training, cognitive restructuring and individually-tailored VR exposures (the therapist can manipulate the turbulence level and other flight-related variables to fit participants' fears and current progress).
Study: NCT02765451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interventions of the Cancéropôle Nord-Ouest
Description: During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,.....

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interventions of the Cancéropôle Nord-Ouest
Description: During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,.....
Study: NCT01825031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 100mg once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: a single dose 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300mg taken immediately in combination with cotrimoxazole

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Supplementary Food
Description: 2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
Study: NCT00816374

Intervention type: OTHER
Group type: OTHER
Intervention: Reading materials and discussions
Description: We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~* The American Cancer Society~* The American Academy of Dermatology~* The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~* Sun protection practices~* Risk factors for melanoma~* Information about what melanoma looks like~* How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets.

Intervention type: OTHER
Group type: OTHER
Intervention: Reading materials and discussions
Description: We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~* Melanoma and skin cancer protection guidelines~* The benefits of skin screening practices~* Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~* knowledge of melanoma~* current and past skin cancer screening practices~* current and past sun protection practices~* attitudes about skin cancer and sun protection~* feelings about relative's melanoma diagnosis and treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~* knowledge of melanoma~* current and past skin cancer screening practices~* current and past sun protection practices~* attitudes about skin cancer and sun protection~* feelings about relative's melanoma diagnosis and treatment
Study: NCT04233749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: 325mg of tranexamic acid twice daily for six months
Study: NCT04202731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBS Study
Description: Sleep extension intervention
Study: NCT01903499

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Bean patty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Bean patty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Beef patty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Beef patty
Study: NCT00243659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ReFacto AF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ReFacto AF
Study: NCT03299920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized instructions
Description: Specific instructions related to peripheral nerve block.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional instructions
Description: Usual post-operative instructions.
Study: NCT01975168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handylaser Trion laser acupuncture
Description: intervention interval is 3 times per week for 12 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Handylaser Trion laser acupuncture
Description: intervention interval is 3 times per week for 12 weeks
Study: NCT04446364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanolic extract of Aloe vera gel cavity disinfectant
Description: Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethanolic extract of Aloe vera gel cavity disinfectant
Description: Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorohexadine
Description: 2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorohexadine
Description: 2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
Study: NCT02788864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arterakine (DHA/piperaquine)
Description: Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
Study: NCT00755833

Intervention type: DRUG
Intervention: biphasic insulin aspart 50
Description: Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
Study: NCT00038350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lingual Strengthening
Description: 8 week lingual strengthening exercise protocol
Study: NCT01541397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin
Description: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
Study: NCT03290495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: a similar volume of normal saline 0.9% for intravenous injection instead of ketamine will be given to the control group. this because the attending anesthesiologist will be blinded to the study drugs and aim according to the study proposal.
Study: NCT04264897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (Hunter Pharmacy) following a ramp up dosing protocol with a targeted dose of 1500 mg/day for 12 weeks.
Study: NCT00940264

Intervention type: PROCEDURE
Intervention: transvaginal hybrid cholecystectomy
Description: transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
Study: NCT03347071

Intervention type: BEHAVIORAL
Intervention: Prevention Course Group
Description: The undergraduate prevention course is structured around Eat Breathe Thrive Program curriculum. The course aims to teach somatic practices, provide healthy tools for emotional regulation, allow for the creation of community-based networks of support, foster a sense of meaning and purpose through service activities, and practice these learned skills through yoga.
Study: NCT02179229

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: Placebo will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SYNBIOTIC
Description: Probinul Neutro® will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
Study: NCT01614093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Single dose intranasal oxytocin (24 IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Single dose intranasal oxytocin (24 IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo- Sugar pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo- Sugar pill
Study: NCT02747030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin intravenously
Description: Retinal vein cannulation with Ocriplasmin infusion
Study: NCT01647607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's Intervention (YWI)
Description: This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention (PAI)
Description: This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
Study: NCT04494932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-Locking Tenotomy
Description: Self-locking Tenotomy describes the surgical procedure that will be performed to treat SLAP tears.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biceps Tenodesis
Description: Biceps tenodesis describes the surgical procedure that will be performed to treat SLAP tears.
Study: NCT00836433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONNECT educational intervention
Description: The CONNECT educational intervention is a training program for staff to improve communication with a more dense network of co-workers, in order to improve resident problem-solving. Includes in class sessions, group and individual mapping exercises, self-monitoring of interactions, and individual staff coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FALLS educational intervention
Description: FALLS is a traditional falls quality improvement education program including online modules, audit and feedback, and academic detailing sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FALLS educational intervention
Description: FALLS is a traditional falls quality improvement education program including online modules, audit and feedback, and academic detailing sessions